MARKET

STML

Stemline
STML
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-6.4822
11.22
4.207
621,202,586.55
News
Financial
Releases
Corp Actions
Analysis
Profile
European advisory group backs Stemline's Elzonris for rare blood cancer
After re-examining its initial negative opinion issued in July, the European Medicines Agency's advisory group CHMP has reversed itself and now recommends approval of Stemline Therapeutics' (STML) Elzonris (tagraxofusp) for
Seekingalpha · 11/13 13:03
European advisory group thumbs down on Stemline's Elzonris
The European Medicines Agency's advisory group CHMP has adopted a negative opinion against approval of Stemline Therapeutics' (STML) Elzonris (tagraxofusp)
seekingalpha · 07/24 20:12
Stemline Therapeutics acquired by Menarini Group
Seeking Alpha - Article · 06/10 14:13
Lifshitz Law Firm, P.C. Announces Investigation of Franklin Financial Network, Inc., Mobile Mini, Inc., Portola Pharmaceuticals, Inc., resTORbio, Inc., Stemline Therapeutics, Inc., Taubman Centers, Inc. and Willis Towers Watson Public Limited Company and Wright Medical Group N.V.
PR Newswire · 05/28 15:11
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations
GlobeNewswire · 05/21 19:10
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm
GlobeNewswire · 05/19 17:23
KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
GlobeNewswire · 05/19 15:14
Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. (KLXE), Quintana Energy Services, Inc. (QES), Portola Pharmaceuticals, Inc. (PTLA), and Stemline Therapeutics, Inc. (STML)
GlobeNewswire · 05/15 19:39
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of STML. Analyze the recent business situations of Stemline through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average STML stock price target is 11.80 with a high estimate of 12.50 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 105
Institutional Holdings: 36.50M
% Owned: 69.52%
Shares Outstanding: 52.51M
TypeInstitutionsShares
Increased
37
5.31M
New
17
2.16M
Decreased
28
2.75M
Sold Out
17
2.26M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Ivan Bergstein
Chief Operating Officer
Kenneth Hoberman
Senior Vice President - Finance/Chief Accounting Officer
David Gionco
Other
Robert Francomano
Independent Director
Ron Bentsur
Independent Director
Darren Cline
Independent Director
Alan Forman
Independent Director
Daniel Hume
Independent Director
Mark Sard
Independent Director
Kenneth Zuerblis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of Stemline stock information, including NASDAQ:STML real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STML stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STML stock methods without spending real money on the virtual paper trading platform.